{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T08:41:54Z","timestamp":1696408914774},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T00:00:00Z","timestamp":1452211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>The aim of the study was to simplify the dosing regimen of peginterferon alfa\u20102a in paediatric patients with chronic hepatitis C.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A population pharmacokinetic (PK) model was developed using PK data from 14 children aged 2\u20138 years and 402 adults. Simulations were produced to identify a simplified dosing regimen that would provide exposures similar to those observed in the paediatric clinical trials and in the range known to be safe\/efficacious in adults. Model predictions were evaluated against observed adult and paediatric data to reinforce confidence of the proposed dosing regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The final model was a two compartment model with a zero order resorption process. Covariates included a linear influence of body surface area (BSA) on apparent oral clearance (CL\/<jats:italic>F<\/jats:italic>) and a linear influence of body weight on apparent volume of distribution of the central compartment (<jats:italic>V<\/jats:italic><jats:sub>1<\/jats:sub>\/<jats:italic>F<\/jats:italic>). A simplified dosing regimen was developed which is expected to provide exposures in children aged \u22655\u00a0years similar to the dosing formula used in the paediatric clinical trial and within the range that is safe\/efficacious in adults. This simplified regimen is approved in the EU and in other countries for the treatment of chronic hepatitis C in treatment\u2010naive children\/adolescents aged \u22655\u00a0years in combination with ribavirin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Pre\u2010existing adult PK data were combined with relatively limited paediatric PK data to develop a PK model able to predict exposure in both populations adequately. This provided increased confidence in characterizing PK in children and helped in the development of a simplified dosing regimen of peginterferon alfa\u20102a in paediatric patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12816","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T15:56:23Z","timestamp":1446566183000},"page":"658-666","source":"Crossref","is-referenced-by-count":0,"title":["Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa\u20102a dosing regimen for children with hepatitis C"],"prefix":"10.1111","volume":"81","author":[{"given":"Barbara J.","family":"Brennan","sequence":"first","affiliation":[{"name":"Hoffmann\u2010La Roche Inc.  Nutley NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabelle","family":"Lemenuel\u2010Diot","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2013La Roche Ltd  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Snoeck","sequence":"additional","affiliation":[{"name":"SGS Exprimo NV  Mechelen Belgium and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"McKenna","sequence":"additional","affiliation":[{"name":"Roche Products Ltd  Welwyn UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Solsky","sequence":"additional","affiliation":[{"name":"Hoffmann\u2010La Roche Inc.  Nutley NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Wat","sequence":"additional","affiliation":[{"name":"Roche Products Ltd  Welwyn UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navita L.","family":"Mallalieu","sequence":"additional","affiliation":[{"name":"Hoffmann\u2010La Roche Inc.  Nutley NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,8]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"HepatitisC. Fact sheet No. 164. Geneva: World Health Organization; July2012. Available at:http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/index.html(last accessed 3 March 2014)."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.105.4.836"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S5078"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-41631"},{"key":"e_1_2_9_7_1","first-page":"190A","article-title":"Branched methoxy 40 KDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon alfa\u20102a (PEG\u2010IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC)","volume":"30","author":"Algranati N","year":"1999","journal-title":"Hepatology"},{"key":"e_1_2_9_8_1","unstructured":"PEGASYS\u00ae prescribing information. Hoffmann\u2010La Roche Inc Nutley NJ USA. Revised 2013."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000235974.67496.e6"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.047"},{"key":"e_1_2_9_11_1","volume-title":"Handbook of basic pharmacokinetics \u2010 including clinical applications","author":"Ritschel WA","year":"1999"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.07.003"},{"key":"e_1_2_9_13_1","first-page":"394A","article-title":"The pharmacokinetic behaviour of pegylated (40 KDa) interferon alfa\u20102a (Pegasys\u2122) in chronic hepatitis C patients after multiple dosing","volume":"32","author":"Modi MW","year":"2000","journal-title":"Hepatology"},{"key":"e_1_2_9_14_1","volume-title":"NONMEM user's guide","author":"Beal SL","year":"1991"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03349.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03470.x"},{"key":"e_1_2_9_17_1","first-page":"1","article-title":"2000 CDC Growth charts for the United States: methods and development","volume":"11","author":"Kuczmarski RJ","year":"2002","journal-title":"Vital Health Stat"},{"key":"e_1_2_9_18_1","unstructured":"INTRON\u00ae. A prescribing information. Manufactured by Schering Corporation a subsidiary of Merck & Co. Inc 1462 Whitehouse Station NJ 08889 USA. Revised 2011."},{"key":"e_1_2_9_19_1","unstructured":"PegIntron prescribing information. Manufactured by Schering Corporation a subsidiary of Merck & Co. Inc 1462 Whitehouse Station NJ 08889 USA Revised 2011."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002800203600501"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12816","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T03:58:51Z","timestamp":1696305531000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,8]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/bcp.12816"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12816","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,8]]}}}